CardioAdvocate Rounds
Pull up a chair. We saved you a seat.
This Week in 30 Seconds
- HORIZON missed its primary endpoint — but the Lp(a) story isn’t over. Pelacarsen lowered Lp(a) by ~80% but didn’t reduce cardiovascular events in a secondary prevention population already receiving aggressive background therapy. The question isn’t whether Lp(a) matters — it’s whether we tested the right population. Full data at AHA Scientific Sessions in 11 days.
- Conference season begins Saturday. TCT 2026 in San Diego kicks off October 31, followed immediately by AHA in Chicago (Nov 6–9). The cardiometabolic headlines at AHA: full HORIZON data, ZEUS (ziltivekimab for inflammation), SYNCHRONIZE-CVOT (survodutide), STREAM (statin discontinuation in the elderly), and ATTAIN-OSA (tirzepatide for obstructive sleep apnea).
- New on CardioAdvocate — Four new Insights articles this month: Peptides, Creatine, Red Red Wine, and a 4-part healthcare costs series launching soon. The biggest content month in CardioAdvocate history.
The Lead
HORIZON: What a Negative Top-Line Result Really Means for Lp(a)
On September 4, Novartis announced that pelacarsen missed its primary endpoint in the Lp(a)HORIZON trial. The antisense oligonucleotide lowered Lp(a) by approximately 80% in 8,323 patients with elevated Lp(a) and established ASCVD — but that dramatic biochemical reduction did not translate into fewer cardiovascular events.
Headlines immediately declared the Lp(a) hypothesis dead. That conclusion is premature.
HORIZON enrolled a secondary prevention population — patients who already had cardiovascular disease and were already receiving aggressive, guideline-directed medical therapy. LDL-C levels were well controlled. PCSK9 inhibitors, high-intensity statins, and ezetimibe were widely used. When you’ve already reduced residual risk as much as current therapies allow, detecting an incremental benefit from targeting one additional pathway becomes extremely difficult. The event rate was likely lower than projected, and the signal-to-noise ratio was working against the drug from the start.
We explored this in depth in our recent analysis, Victims of Our Own Success, which examines why this trial’s design may have worked against finding a signal. There are several reasons HORIZON may have failed that have nothing to do with whether Lp(a) is causal:
- Wrong population: Secondary prevention patients on maximal therapy may have too little residual Lp(a)-attributable risk to modify. A primary prevention cohort with elevated Lp(a) as their dominant risk driver might tell a different story.
- Lp(a) threshold: Were enough patients at very high levels (≥150 nmol/L or ≥60 mg/dL) enrolled to see a signal where the risk is most concentrated?
- Duration and power: Was follow-up long enough? Was the trial powered to detect a benefit on top of optimized background therapy?
- Mechanism: Lp(a) carries oxidized phospholipids and has prothrombotic properties beyond its cholesterol content. A drug that lowers the particle number may not fully neutralize these pathogenic mechanisms.
The full HORIZON data will be presented at AHA Scientific Sessions on November 7. Subgroup analyses — particularly by baseline Lp(a) level and background therapy intensity — will be the most closely watched slides in Chicago. Meanwhile, Amgen’s OCEAN(a)-Outcomes trial of olpasiran (an siRNA with a different mechanism of Lp(a) lowering) is still enrolling and will provide a second, independent test of the hypothesis.
What has not changed: Universal Lp(a) screening remains a Class I recommendation in the 2026 ACC/AHA Dyslipidemia Guidelines. Knowing your Lp(a) level still matters — it informs risk stratification, shared decision-making, and how aggressively to treat LDL-C and other modifiable risk factors. What has changed is the timeline: a specific Lp(a)-lowering drug is not coming as quickly as many hoped. But a negative trial in a population that may not have been ideal is not the same thing as a disproven hypothesis.
The screening conversation hasn’t changed. Every adult deserves at least one Lp(a) measurement. What has changed is the treatment conversation. There is currently no approved drug that specifically lowers Lp(a) to prevent cardiovascular events. But elevated Lp(a) is still a powerful reason to be more aggressive with everything else: push LDL-C lower, optimize blood pressure, address insulin resistance, and consider PCSK9 inhibitors or Lipfendra (enlicitide) if LDL-C isn’t at the most aggressive target the patient’s risk profile warrants. An elevated Lp(a) on top of an elevated LDL-C is a compounding risk, not a parallel one.
“I heard the Lp(a) drug trial didn’t work. My Lp(a) is elevated — does that still matter? And given that we can’t lower my Lp(a) with a drug yet, should we be more aggressive with my LDL and other risk factors?”
What’s Hot
ZEUS: The Inflammation Hypothesis Takes Another Hit
Separate from the Lp(a) story, the anti-inflammatory hypothesis faced its own reckoning this summer. On July 31, Novo Nordisk reported that ziltivekimab failed to reduce MACE in the ZEUS trial — hazard ratio 0.99 (95% CI 0.88–1.11) in over 6,300 patients with ASCVD, CKD, and elevated hsCRP.
Ziltivekimab is a monoclonal antibody that blocks interleukin-6 (IL-6), the cytokine upstream of CRP. The drug hit its pharmacologic target beautifully — free IL-6 and CRP dropped dramatically. But the events didn’t budge. Not even a trend. HR 0.99.
This matters because the inflammation hypothesis had a credible foundation. CANTOS (canakinumab, targeting IL-1β) showed a modest cardiovascular benefit in 2017, though it was never commercialized. ZEUS went upstream to IL-6 directly — a cleaner pharmacologic approach. The result suggests one of two things: either the residual inflammatory risk captured by CRP isn’t a single, druggable pathway, or the right patients, dose, or combination hasn’t been found. We’ve covered the full history of this hypothesis — from CANTOS to CIRT to ZEUS — in our Phenotype deep dive, The Itch That Rashes: Inflammation & CRP. Two companion trials — HERMES (heart failure) and ARTEMIS (post-MI) — will report in early 2027 and may tell us which interpretation is correct.
For now, colchicine remains the only anti-inflammatory with positive cardiovascular outcomes data (LoDoCo2, COLCOT). And lifestyle modification — addressing visceral adiposity, insulin resistance, poor sleep, and metabolic dysfunction — remains the most effective way to lower chronic inflammation.
For patients with persistently elevated hsCRP despite optimized lipid therapy: colchicine 0.5 mg daily is the evidence-based option. Beyond that, focus on the metabolic drivers of inflammation. Weight loss in patients with visceral obesity, treatment of OSA, glycemic optimization, and exercise all lower CRP through mechanisms that target multiple pathways — not just one cytokine.
AHA Scientific Sessions Preview: The Cardiometabolic Trials to Watch
AHA Scientific Sessions 2026 opens November 6 in Chicago with 23 late-breaking studies. The cardiometabolic lineup is stacked:
SYNCHRONIZE-CVOT — Survodutide Cardiovascular Outcomes. Boehringer Ingelheim’s dual GLP-1/glucagon receptor agonist goes head-to-head with the cardiovascular outcomes question. If survodutide shows CV benefit in obesity, it opens a third lane in the incretin space beyond semaglutide and tirzepatide — and validates glucagon receptor agonism as additive rather than counterproductive. Presentation Sunday, November 8.
STREAM — Statin Discontinuation in Older Adults. Should we stop statins in patients over 75 who’ve been taking them for years? STREAM randomized elderly statin users to continuation vs. discontinuation. This trial is clinically important because the question comes up in every geriatric practice — and right now the answer is based on opinion, not evidence. Combined with the positive STAREE trial (statins preventing disability and death in healthy elderly), the statin-in-aging picture is getting clearer. Presentation Saturday, November 7.
ATTAIN-OSA — Tirzepatide for Obstructive Sleep Apnea. Following the SURMOUNT-OSA results, tirzepatide is being tested specifically for OSA outcomes. Sleep apnea is one of the most undertreated cardiometabolic risk multipliers — it worsens hypertension, insulin resistance, atrial fibrillation, and heart failure. If GLP-1 RAs can treat OSA as effectively as CPAP (or better, given adherence), the implications are enormous. Presentation Sunday, November 9.
CTX310 Gene-Editing Update. Verve Therapeutics presents updated data on their CRISPR-based approach to permanently lowering Lp(a) via ANGPTL3 editing. Last year’s one-year data showed durable reductions in triglycerides and LDL-C. The question now: how durable is it, and how does the safety profile hold? This is the gene-editing-for-lipids story to follow.
- Full HORIZON data — The subgroup analyses everyone is waiting for. Pay attention to outcomes by baseline Lp(a) level and by background therapy intensity.
- Full ZEUS data — Will subgroup analyses identify a population where IL-6 inhibition showed signal?
- OCEANIC-STROKE — Factor XIa inhibition (abelacimab) for stroke prevention in atrial fibrillation. A potential paradigm shift in anticoagulation.
“I’m overweight and have sleep apnea and high cholesterol. I’ve been hearing a lot about these new GLP-1 medications. Are any of the studies coming out at the heart meetings this month relevant to my situation?”
Myth-Buster of the Week
BUSTED: “GLP-1 Agonists Are Just Weight Loss Drugs”
The myth: Semaglutide, tirzepatide, and their cousins are diet drugs with a fancy price tag. The cardiovascular benefits are just a byproduct of weight loss — nothing special about the drugs themselves.
Why it’s wrong: The SELECT trial showed a 20% reduction in major adverse cardiovascular events with semaglutide in patients with obesity and established cardiovascular disease — and the benefit appeared before significant weight loss occurred. STEP-HFpEF showed dramatic improvements in heart failure symptoms and functional capacity with semaglutide in patients with HFpEF and obesity. FLOW showed kidney protection in patients with type 2 diabetes and CKD. These aren’t weight loss trials that happened to measure cardiac endpoints — they’re cardiovascular and organ-protection trials that happen to also cause weight loss.
GLP-1 receptor agonists reduce inflammation (measured by CRP), improve endothelial function, reduce hepatic fat, lower blood pressure, and improve lipid profiles — all through mechanisms that extend well beyond the number on the scale. The cardiovascular benefit appears to be a direct pharmacologic effect, not just a consequence of being lighter.
The bottom line: These are cardiometabolic drugs that also cause weight loss — not the other way around. The weight loss matters too, of course. But framing them as “diet drugs” misses the most important part of the story. With SYNCHRONIZE-CVOT (survodutide), ATTAIN-OSA (tirzepatide for OSA), and multiple other incretin trials reporting at AHA, the evidence base is only getting stronger.
“I know GLP-1 medications help with weight loss, but I’ve heard they also protect the heart and kidneys. Given my risk factors, would one of these medications make sense for me — not just for weight, but for my overall cardiometabolic health?”
New on CardioAdvocate
October was the biggest content month in CardioAdvocate history. Four new deep-dive Insights articles, all live now:
- Peptides: Wild West or New Frontier? — Compounded semaglutide, BPC-157, and “research peptides” are flooding gyms and med spas. We unpack the science, the FDA crackdown, and what your doctor needs to know.
- Creatine! We’re Gonna Pump You Up! — The most studied supplement in sports nutrition, held to a real evidentiary standard. What it actually does for muscle, brain, and metabolic health.
- Red Red Wine, Stay Close to Me — The “Not a Single Drop” doctrine has dominated headlines — but the evidence tells a more nuanced story. We dissect the J-curve debate.
- Coming Soon: Why Does Healthcare Cost So Much? — A 4-part investigative series on PBMs, hospital facility fees, private equity, and the physician pay myth. Part 1, “The Drug Pricing Machine,” drops soon.
On the Horizon
🗓 Oct 31 – Nov 3: TCT 2026 — San Diego. 28 late-breaking studies focused on interventional cardiology. Key cardiometabolic crossover: lipid-lowering strategies in ACS patients and heparin-dosing optimization in PCI (HD-PCI). CardioAdvocate will cover the practice-changing findings.
🗓 Nov 6 – 9: AHA Scientific Sessions 2026 — Chicago. 23 late-breakers. Saturday Nov 7: Full ZEUS and HORIZON data, STREAM (statin discontinuation in elderly). Sunday Nov 8–9: SYNCHRONIZE-CVOT (survodutide), ATTAIN-OSA (tirzepatide for OSA), CTX310 gene-editing update, OCEANIC-STROKE (factor XIa inhibition).
🗓 Nov 14 – 17: ObesityWeek 2026 — Washington, D.C. The Obesity Society’s annual meeting. Expect new data on tirzepatide, retatrutide, orforglipron, and the next wave of incretin-based therapies.
🗓 December: 24th WCIRDC — Los Angeles. World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease. Up to 27 CME credits. The premier cardiorenal metabolic crossover meeting.
CardioAdvocate Toolkit
This Week’s Action Items — By Patient Type
HORIZON’s top-line miss does not mean your Lp(a) doesn’t matter. It means we tested a drug in a population that may not have been ideal — and we’re still waiting for the subgroup data and a second trial (OCEAN(a)-Outcomes). Your action plan: (1) Make sure your LDL-C is at the most aggressive target your risk profile warrants under the 2026 guidelines. Elevated Lp(a) is a reason to push LDL lower, not an excuse to wait for a future drug. (2) Optimize every other modifiable risk factor — blood pressure, A1c, exercise, weight. (3) Ask your doctor whether PCSK9 inhibitors or Lipfendra (enlicitide) should be on the table if you’re not at goal.
ZEUS showed that blocking IL-6 alone didn’t reduce events. But chronic inflammation still matters — it’s just not a single-cytokine problem. Focus on the metabolic roots: visceral fat, insulin resistance, poor sleep, OSA, and sedentary behavior all drive chronic low-grade inflammation. Colchicine 0.5 mg daily remains an option for patients with established ASCVD and elevated CRP. Ask your doctor if it makes sense for you.
Conference season means your cardiologist is absorbing massive amounts of new data over the next three weeks. Come prepared: download a MyCardioAdvocate™ visit brief for your condition, write down your questions, and ask specifically whether any recent study changes your treatment plan. The question “Has anything come out of the recent meetings that applies to me?” is always a good one.
The Foot Stomper
The biggest month in cardiology starts Saturday. TCT, AHA, and ObesityWeek — three conferences in three weeks. By Thanksgiving, we’ll have answers on survodutide’s cardiovascular profile, statin use in the elderly, tirzepatide for sleep apnea, and whether gene editing can durably rewrite lipid biology.
But the most important data presentation may be the one we’ve already half-read. The full HORIZON results at AHA will tell us whether there is a subpopulation where Lp(a) lowering does reduce risk — patients with the highest Lp(a) levels, or those in whom background therapy leaves more residual Lp(a)-attributable risk exposed. A negative top-line result does not always mean a dead hypothesis. Sometimes it means we asked the right question in the wrong population.
That’s the nature of clinical science. It doesn’t always give us the answer we wanted, but it always tells us something we needed to know. The Lp(a) story has a next chapter. So does the inflammation story. And the GLP-1 story is still being written in real time.
Conference season is here. Pay attention. Ask questions. Stay curious. Advocate.
© 2026 CardioAdvocate.com | cardioadvocate.com